[HTML][HTML] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study
YL Wu, JH Kim, K Park, A Zaatar, G Klingelschmitt… - Lung cancer, 2012 - Elsevier
Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
[HTML][HTML] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - Elsevier
Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
JW Neal - Future Oncology, 2010 - Taylor & Francis
The first-line treatment of advanced non-small-cell lung cancer (NSCLC) generally consists
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Anti-cancer drugs, 2011 - journals.lww.com
Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2
R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
[HTML][HTML] A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 …
JG Aerts, H Codrington, NAG Lankheet, S Burgers… - Annals of oncology, 2013 - Elsevier
Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
相关搜索
- cell lung cancer
- erlotinib maintenance therapy
- lung cancer survival benefit
- lung cancer maintenance treatment
- lung cancer sequential erlotinib
- lung cancer trial of erlotinib
- lung cancer asian patients
- lung cancer disease progression
- lung cancer standard chemotherapy
- lung cancer randomized phase
- lung cancer performance status
- lung cancer maintenance erlotinib
- maintenance therapy pooled analysis
- asian patients maintenance erlotinib
- disease progression maintenance erlotinib
- standard chemotherapy trial of erlotinib